SEC Form SC 13G filed by Galera Therapeutics Inc.

1/2/24 8:35:10 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GRTX alert in real time by email

SC 13G 1 0001362033-24-00001.txt Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.__)* (Name of Issuer) : Galera Therapeutics ORD (Title of Class of Securities) : Common Stock (CUSIP Number) : 36338D108 (Date of Event Which Requires Filing of this Statement) : 31/12/2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d?1(b) [X] Rule 13d?1(c) [ ] Rule 13d?1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be ?filed? for the purpose of Section 18 of the Securities Exchange Act of 1934 (?Act?) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 89853L2034 (1) Names of reporting persons: GSA Capital Partners LLP (2) Check the appropriate box if a member of a group (a) (see instructions) (b) (3) SEC use only (4) Citizenship or place of organization : United Kingdom Number of shares beneficially owned by each reporting person with: 3892561 (5) Sole voting power Yes (6) Shared voting power No (7) Sole dispositive power Yes (8) Shared dispositive power No (9) Aggregate amount beneficially owned by each reporting person 3892561 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 7.156% (12) Type of reporting person (see instructions): IA Page 2 of 2 Pages Special Instructions for Complying With Schedule 13G Under Sections 13(d), 13(g) and 23 of the Securities Exchange Act of 1934 and the rules and regulations thereunder, the Commission is authorized to solicit the information required to be supplied by this schedule by certain security holders of certain issuers. Disclosure of the information specified in this schedule is mandatory. The information will be used for the primary purpose of determining and disclosing the holdings of certain beneficial owners of certain equity securities. This statement will be made a matter of public record. Therefore, any information given will be available for inspection by any member of the public. Because of the public nature of the information, the Commission can use it for a variety of purposes, including referral to other governmental authorities or securities self- regulatory organizations for investigatory purposes or in connection with litigation involving the Federal securities laws or other civil, criminal or regulatory statutes or provisions. Failure to disclose the information requested by this schedule may result in civil or criminal action against the persons involved for violation of the Federal securities laws and rules promulgated thereunder. Instructions. A. Statements filed pursuant to Rule 13d?1(b) containing the information required by this schedule shall be filed not later than February 14 following the calendar year covered by the statement or within the time specified in Rules 13d?1(b)(2) and 13d?2(c). Statements filed pursuant to Rule 13d?1(d) shall be filed within the time specified in Rules 13d?1(c), 13d?2(b) and 13d?2(d). Statements filed pursuant to Rule 13d?1(c) shall be filed not later than February 14 following the calendar year covered by the statement pursuant to Rules 13d?1(d) and 13d?2(b). B. Information contained in a form which is required to be filed by rules under section 13(f) (15 U.S.C. 78m(f)) for the same calendar year as that covered by a statement on this schedule may be incorporated by reference in response to any of the items of this schedule. If such information is incorporated by reference in this schedule, copies of the relevant pages of such form shall be filed as an exhibit to this schedule. C. The item numbers and captions of the items shall be included but the text of the items is to be omitted. The answers to the items shall be so prepared as to indicate clearly the coverage of the items without referring to the text of the items. Answer every item. If an item is inapplicable or the answer is in the negative, so state. Item 1(a) Name of issuer: Galera Therapeutics ORD Item 1(b) Address of issuer's principal executive offices: 2 West Liberty Blvd, Suite 110, Malvern, PA 19355, United States 2(a) Name of person filing: GSA Capital Partners LLP 2(b) Address or principal business office or, if none, residence: 5 Stratton Street, London, United Kingdom 2(c) Citizenship: UK 2(d) Title of class of securities: Common Stock 2(e) CUSIP No: 89853L203 Item 3. If this statement is filed pursuant to 240.13d?1(b) or 240.13d?2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a?8); (e) [ ] An investment adviser in accordance with 240.13d? 1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with 240.13d?1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with 240.13d?1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a?3); (j) [ ] A non-U.S. institution in accordance with 240.13d? 1(b)(1)(ii)(J); (k) [ ] Group, in accordance with 240.13d?1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d? 1(b)(1)(ii)(J), please specify the type of institution: ________ Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 3892561 (b) Percent of class: 7.156% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 3892561. (ii) Shared power to vote or to direct the vote 0. (iii) Sole power to dispose or to direct the disposition of 3892561. (iv) Shared power to dispose or to direct the disposition of 0. Instruction. For computations regarding securities which represent a right to acquire an underlying security see 240.13d?3(d)(1). Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Instruction. Dissolution of a group requires a response to this item. Item 6. Ownership of More than 5 Percent on Behalf of Another Person. If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. If a parent holding company or control person has filed this schedule pursuant to Rule 13d?1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d? 1(c) or Rule 13d?1(d), attach an exhibit stating the identification of the relevant subsidiary. Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to 240.13d? 1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d?1(c) or Rule 13d?1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group. Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications (a) The following certification shall be included if the statement is filed pursuant to 240.13d?1(b): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a?11. (b) The following certification shall be included if the statement is filed pursuant to 240.13d?1(b)(1)(ii)(J), or if the statement is filed pursuant to 240.13d?1(b)(1)(ii)(K) and a member of the group is a non-U.S. institution eligible to file pursuant to 240.13d?1(b)(1)(ii)(J): By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to [insert particular category of institutional investor] is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D. (c) The following certification shall be included if the statement is filed pursuant to 240.13d?1(c): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a?11. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: 01/02/2024 Signature. Timothy Kuschill Name/Title. General Counsel and Chief Compliance Officer The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, Provided, however, That a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Get the next $GRTX alert in real time by email

Date	Price Target	Rating	Analyst
8/10/2023	$6.00 → $0.50	Overweight → Neutral	Piper Sandler
12/20/2021	$11.00 → $20.00	Buy	Citigroup
12/15/2021	$10.00	Neutral → Buy	HC Wainwright & Co.
12/15/2021	$15.00	Neutral → Buy	BTIG
10/20/2021		Buy → Neutral	HC Wainwright & Co.
10/19/2021	$17.00 → $2.00	Buy → Underperform	BofA Securities
10/19/2021		Buy → Neutral	BTIG Research

SEC Form SC 13G filed by Galera Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for $GRTX

$GRTX Press Releases

Fastest customizable press release news feed in the world

Galera Therapeutics completes acquisition of Nova Pharmaceuticals

Galera Announces Board Approval of Complete Liquidation and Dissolution

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

$GRTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Galera downgraded by Piper Sandler with a new price target

Citigroup reiterated coverage on Galera Therapeutics with a new price target

Galera Therapeutics upgraded by HC Wainwright & Co. with a new price target

$GRTX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Chang Nancy T bought $499,979 worth of shares (7,644,932 units at $0.07) (SEC Form 4)

Schneid Yair bought $590,424 worth of shares (2,780,407 units at $0.21), increasing direct ownership by 35% to 10,823,610 units (SEC Form 4) (Amendment)

Schneid Yair bought $166,417 worth of shares (932,402 units at $0.18), increasing direct ownership by 13% to 8,043,203 units (SEC Form 4)

$GRTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$GRTX SEC Filings

$GRTX Leadership Updates

Live Leadership Updates

SEC Form 4 filed by Chief Accounting Officer Sussman Joel F.

SEC Form 4 filed by President and CEO Sorensen Mel

SEC Form 4 filed by Director Lokay Kevin G

SEC Form 8-K filed by Galera Therapeutics Inc.

SEC Form 10-K filed by Galera Therapeutics Inc.

Amendment: Galera Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

Galera Expands Commercial Leadership Team

Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer

Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer

$GRTX Financials

Live finance-specific insights

Galera Therapeutics completes acquisition of Nova Pharmaceuticals

Galera Adopts Limited Duration Stockholder Rights Agreement

Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese

$GRTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Galera Therapeutics Inc. (Amendment)

SEC Form SC 13G filed by Galera Therapeutics Inc.

SEC Form SC 13G/A filed by Galera Therapeutics Inc. (Amendment)

Recent Analyst Ratings for
$GRTX

$GRTX
Press Releases

$GRTX
Analyst Ratings

$GRTX
Insider Purchases

$GRTX
Insider Trading

$GRTX
SEC Filings

$GRTX
Leadership Updates

$GRTX
Financials

$GRTX
Large Ownership Changes